Apr 30, 2024
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Dec 03, 2020
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO(TM) (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
Dec 03, 2020
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO(TM) (lumasiran)
May 18, 2020
Infectious Diseases Partnering Terms and Agreements, 2014 to 2020
Feb 11, 2020
NORD Introduces This Year's Rare Disease-Fighting Super Group: The 2020 Rare Impact Award Honorees!
Dec 12, 2019
PANTHERx® Rare Pharmacy Selected by Alnylam Pharmaceuticals to Distribute GIVLAARI(TM) (givosiran)
Oct 14, 2019
Global RNA Interference (RNAi) Industry
Sep 24, 2019
Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources
Aug 13, 2019
RNAi Technologies Market 2019, Industry Analysis, Competitors Strategy, Trends and Demands, Key Applications, Forecast To 2025
Aug 07, 2019
Ionis Reports Second Quarter 2019 Financial Results
Jul 23, 2019
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
Apr 26, 2019
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Apr 08, 2019
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Nov 19, 2018
Amyloidosis Treatment Market Worth $6.7 Billion by 2025 | CAGR: 7.2%: Grand View Research, Inc.
Nov 13, 2018
Global $6.7 Billion Amyloidosis Treatment Market to 2023 - Key Players are Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda
Oct 29, 2018
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
Oct 03, 2018
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Alnylam Pharmaceuticals, Inc. - ALNY
Sep 27, 2018
ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY
Sep 27, 2018
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm
Sep 27, 2018
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018